Wednesday, July 8, 2026

Drug profile · INN

vadadustat

vadadustat (VAFSEO) is a egl nine homolog 3 inhibitor. Associated with Akebia Europe Limited. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved PMDA: approved
US status approved
Patents linked 18
Pipeline programs 13
News articles 0
Drug details — vadadustat
US status
approved
Class
Route
ORAL
Patents
18
Programs
13
Data quality
0.89

Quick answer

vadadustat (VAFSEO) is a egl nine homolog 3 inhibitor. Associated with Akebia Europe Limited. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN vadadustat
Brand VAFSEO
Mechanism Egl nine homolog 3 inhibitor
Target Egl nine homolog 1
Route ORAL
Formulation TABLET

Mechanism of action

Egl nine homolog 3 inhibitor

Primary target: Egl nine homolog 1

Approval history

Authority Status Date
FDA approved
EMA approved
PMDA approved

Pipeline programs

  1. Epoetin alga (Epogen)/vadadustat Phase 3 · Akebia Europe · Anemia Associated With Chronic Kidney Disease
  2. Vadadustat Phase 3 · Akebia Europe · Anemia
  3. Vadadustat Phase 3 · Akebia Europe · Anemia Associated With Chronic Kidney Disease (CKD)
  4. Vadadustat Phase 3 · Akebia Europe · Anemia of Chronic Kidney Disease
  5. Vadadustat 900mg Phase 3 · Akebia Europe · Nonintubated Acute Respiratory Distress Syndrome (ARDS)
  6. Vadadustat Phase 2 · Akebia Europe · Chronic Kidney Disease
  7. vadadustat Phase 2 · Akebia Europe · Acute Respiratory Distress Syndrome
  8. Vadadustat Phase 1 · Akebia Europe · Hepatic Impairment

Related & competitor drugs

  1. enarodustat Egl nine homolog 1 inhibitor
  1. US 11857543

    Compositions and methods for treating anemia

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11844756

    Compositions and methods for treating anemia

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11324734

    Compositions and methods for treating anemia

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11267785

    Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11065237

    Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 10738010

    Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 10246416

    Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 10149842

    Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 9987262

    Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

    Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 9776969

    Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

    Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 9701636

    Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

    Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 9145366

    Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

    Expires Mon Sep 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 8940773

    Prolyl hydroxylase inhibitors and methods of use

    Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 8865748

    Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 8598210

    Prolyl hydroxylase inhibitors and methods of use

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 8343952

    Prolyl hydroxylase inhibitors and methods of use

    Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 8323671

    Prolyl hydroxylase inhibitors and methods of use

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 8133894

    N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones

    Expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is vadadustat?

vadadustat (VAFSEO) is a egl nine homolog 3 inhibitor. Associated with Akebia Europe Limited. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for vadadustat?

VAFSEO is a marketed brand name for vadadustat. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of vadadustat?

vadadustat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.